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Abstract
Background: While aberrant activation of the chromatin-remodeling SWI/SNF complexes has been associated with
cancer development and progression, the role of each subunit in tumor cells is poorly defined. This study is aimed
to characterize the role of SMARCE1/BAF57 in regulating metastasis of breast cancer cells.
Methods: Genetic approaches and chemical inhibitors were used to manipulate the activities of SMARCE1 and its
downstream targets in multiple breast cancer cell lines. Xenograft mouse models were used to analyze the role of
SMARCE1 in lung metastasis in vivo. Nonadherent culture conditions were used to elucidate the role of SMARCE1 in
regulating anoikis. Chromatin immunoprecipitation (ChIP), immunoprecipitation, and immunoblotting assays were
designed to dissect the mechanism of action of SMARCE1. Public databases were used to investigate the
relationship between SMARCE1 deregulation and breast cancer prognosis.
Results: SMARCE1 knockdown reduced lung metastasis of breast cancer cells and sensitized tumor cells to anoikis.
In response to loss of attachment, SMARCE1 interacted with and potentiated transcriptional activity of HIF1A, resulting
in rapid PTK2 activation. Both HIF1A and PTK2 were indispensable for SMARCE1-mediated protection against anoikis by
promoting activation of ERK and AKT pathways while suppressing the expression of pro-apoptotic BIM protein.
Expression data analysis of a large cohort of human breast tumors revealed that high expression of SMARCE1 or
PTK2 is associated with poor prognosis and tumor relapse, and PTK2 expression is positively correlated with SMARCE1
expression in basal-like and luminal B subtypes of breast tumors.
Conclusions: SMARCE1 plays an essential role in breast cancer metastasis by protecting cells against anoikis through
the HIF1A/PTK2 pathway. SMARCE1-mediated PTK2 activation likely plays a key role in promoting metastasis of
basal-like and luminal B subtype of breast tumors.
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Background
Breast cancer is the most frequently diagnosed form of
cancer in American women and is the second leading
cause of cancer-related deaths, primarily due to the in-
curable nature of metastatic breast cancer [1]. Metastasis
is the process whereby cancer cells spread from the site of
the original tumor to distant organs [2]. A stepwise se-
quence of events is involved in the metastatic process,
whereby tumor cells encounter a number of environmental
challenges such as loss of attachment to the extracellular
matrix, physical stress during circulation in blood/lymph
vessels, and immune surveillance [3, 4]. Only a small frac-
tion of disseminated cells are able to alter gene expression
patterns to obtain new phenotypic features according to
environmental cues, and ultimately survive and adapt to
form metastatic lesions.
Chromatin remodeling plays a key role in tumor pro-
gression by altering gene expression patterns to facilitate
rapid adaptation of tumor cells to extracellular stimuli
[5]. Aberrant chromatin remodeling activity is frequently
detected in human tumors. High-throughput genome
and/or exome sequencing studies revealed that the SWI/
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SNF (switching-defective and sucrose nonfermenting)
chromatin-remodeling complexes are the most highly
mutated chromatin regulatory complexes, with nearly
20 % of human cancers harboring mutations in at least one
of the genes encoding SWI/SNF subunits [6]. Human
SWI/SNF complexes consist of either Brahma-related gene
1 (BRG1)/SMARCA4 or Brahma gene (BRM)/SMARCA2
subunit that possesses helicase and ATPase activity, and
several BRG/BRM associated factors (BAFs) that regulate
the DNA-binding specificity and affinity of the complexes
[6, 7]. The cancer-associated mutations cause aberrant
activation of the residual SWI/SNF complexes due to
distinct subunit configurations, rather than eliminating
the chromatin-remodeling activity [8–10]. Although
earlier studies identified several SWI/SNF subunits
(e.g., SMARCB1 and SMARCA4) as tumor repressors,
emerging evidence suggests that SWI/SNF activity is
essential for tumor initiation, maintenance and progres-
sion [10, 11]. Therefore, it becomes important to define
the role of each SWI/SNF subunit in development and
progression of various types of tumors.
Genomic amplification of BAF57/SMARCE1, a core sub-
unit of human SWI/SNF complexes that plays a role in
interaction with transcription factors and chromatin, has
been linked to high risk of recurrence of estrogen/proges-
terone receptor-negative breast tumors [12]. However, the
underlying molecular mechanisms remain undefined. In
this study, we demonstrated that SMARCE1 plays a key
role in breast cancer metastasis by protecting breast cancer
cells against anoikis through the HIF1A/PTK2 pathway.
Methods
Cell culture
All cell lines were purchased from ATCC (Manassas,
VA, USA). MDA-MB-231, HCC38, BT549 and their de-
rivatives were maintained in Minimum Essential Media
(Thermo Fisher Scientific, Rockford, IL, USA) supple-
mented with 10 % fetal bovine serum (FBS), 200 units/ml
penicillin-streptomycin (Cellgro, Manassas, VA, USA) and
0.5 μg/ml amphotericin B (Cellgro, Manassas, VA, USA).
184B5 cells were cultured in Mammary Epithelial Cell
Growth Medium (MEGM, Lonza, Basel, Switzerland). A
lung metastatic derivative of MDA-MB-231 (LM) was
established as previously described [13]. Cells stably ex-
pressing short hairpin RNA (shRNA) against SMARCE1,
HIF1A, PTK2 or empty vector (EV) control were estab-
lished by lentivirus transduction and selected in medium
containing 2 μg/ml puromycin (Sigma-Aldrich, St.
Louis, MO, USA). pLKO.1-HIF1AshRNA (NM_001530.x-
1048s1c1), pLKO.1-SMARCE1shRNA (TRCN0000015779)
and pLKO.1-PTK2shRNA (TRCN0000344599) were ob-
tained from Open Biosystems/GE Dharmacon (Lafayette,
CO, USA). Cells stably expressing focal adhesion kinase
(FAK)/PTK2 or SMARCE1 were obtained by lentiviral
transduction and selected in medium containing 30 μg/
ml blasticidine (Sigma-Aldrich). pLX304-PTK2
(HsCD00442503) and pLX304-SMARCE1
(HsCD00440078) were purchased from DNASU Plas-
mid Repository (Tempe, AZ, USA). Control cells were
established by lentivirus transduction to express selec-
tion marker only. Accell SMARTpool (a mixture of four
short inhibitory RNA (siRNA) provided as a single reagent)
for human SMARCE1 was obtained from Dharmacon (GE
Healthcare Life Sciences, Pittsburgh, PA, USA) and used to
knock down SMARCE1 expression by following the
manufactory’s protocol. The Accell Human Control
siRNA (non-targeting) was used as control
oligonucleotides.
Orthotopic xenograft model and experimental lung
metastasis model (tail vein injection)
All animal studies adhered to protocols approved by
the Institutional Animal Care and Use Committee of
University of Tennessee Health Science Center. For
the orthotopic xenograft model in NOD.Cg Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory,
Bar Harbor, ME, USA), cells (7.5 × 105 cells in 10 μl
phosphate-buffered saline) were surgically inoculated
into the right inguinal mammary gland fat pads of 4-
week-old female mice as previously described [14].
Mice were inspected weekly for tumor appearance by
visual observation and palpation. Primary tumor outgrowth
was monitored twice a week using digital calipers. Tumor
volume was calculated as: volume = (width2 × length)/2.
Tumor and lung tissues were extracted 6 weeks after in-
oculation. The left lung lobes were imaged under the fluor-
escent microscope, fixed with 4 % paraformaldehyde,
followed by tissue section (10 μm) and hematoxylin and
eosin staining. Metastatic loci in lungs were quantified
using ImageJ software. For experimental lung metastasis
model, cells were inoculated into to 4-week-old NSG mice
by tail vein injection. Whole blood was collected by cardiac
puncture at various time and subjected to Ficoll-Paque
separation (Ficoll-Paque PLUS, GE Healthcare Life Sci-
ences, Piscataway, NJ, USA) to isolate circulating tumor
cells. Fluorescent circulating tumor cells were counted
under fluorescent microscope using a ×10 objective.
Quantitation of mRNA using qPCR
Total RNA was prepared with Trizol (Life Technologies,
Grand Island, NY, USA). cDNAs for mRNA were syn-
thesized by using iScript cDNA Synthesis Kits (Bio-Rad,
Hercules, CA, USA). qPCR was performed on the
CFX96™ Real-Time PCR Detection System using SYBR
Green Supermix (Bio-Rad). Expression data of mRNA
were normalized by the 2-ΔΔCT method to RPL13A,
and presented as mean ± SE (n = 3). qPCR primers were
obtained from PrimerBank [15].
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Migration and invasion assays
Cells (20,000 cells/0.5 ml/well) were plated onto control
membrane inserts with 8-micron pores or Matrigel-coated
membrane transwell inserts (BD Biosciences, Bedford, MA,
USA), which are placed in 24-well chambers filled with 0.6
ml growth medium. Twenty-four hours after plating, cells
that remained on the upper surface of the membrane were
removed by cotton-tipped swabs, and cells that migrated/
invaded to the lower surface of the membrane were viewed
under the fluorescent microscope. The percent migration
was expressed as percent migration = (mean number of
cells migrating through Matrigel insert membrane × 100/
mean seeding control) and percent invasion was expressed
as: percent invasion = (mean number of cells invading
through Matrigel insert membrane × 100/mean number of
cells migrating through control insert membrane.
Suspension culture and inhibitor assays
To mimic loss of attachment, cells were seeded in cul-
ture dishes coated with polyHEMA (Sigma-Aldrich) to
prevent cell adherence for various period of time. The
cell suspensions were placed into regular culture dishes
16 h prior to end-point viable cell counting. To identify
the signaling pathways that promote survival of detached
cells, a panel of chemical inhibitors were added in cul-
ture medium: PTK2/FAK inhibitor – 0.5 μM PF562271
(Selleckchem, Houston, TX, USA), ERK1/2 inhibitor –
10 μM U0126 (LC Laboratories, Woburn, MA, USA) or
10 μM PD98059 (Santa Cruz Biotechnology, Dallas, TX,
USA), AKT inhibitor – 30 μM ZSTK474 (LC Laboratories),
TGFBRI/II inhibitor – 10 μM LY210761 (Selleckchem),
SRC inhibitor – 3 μM dasanitib (LC Laboratories) or Notch
inhibitor – 5 μM DAPT (Selleckchem).
Protein extraction and immunoblotting
Protein extraction from whole cell lysates, cytosolic and
nuclear fractions, and immunoblotting with luminescence
detection were performed as previously described [13]. The
following antibodies were used in this study: anti-
PTK2/FAK, FAK-Tyr576P/Tyr577P, ERK1/2-Thr202P/
Fig. 1 SMARCE1 knockdown reduces lung metastasis of breast cancer in vivo. a Expression levels of SMARCE1 mRNA and protein in LM-EV and
LM-SMARCE1-KD cells. b Effect of SMARCE1 knockdown on the growth of xenografts in the fourth inguinal mammary fat pads of female NSG
mice. c Spontaneous lung metastasis from orthotopic sites. Metastatic foci of tumor cells expressing red fluorescent protein on the dorsal surface
of the left lung lobe were imaged 38 days after tumor cell inoculation (upper panel). The presence of tumor cells in the lungs was visualized by
hematoxylin and eosin (H&E) staining of formalin-fixed lung sections (10 μM) and quantified by ImageJ software (lower panel). d Number of
circulating tumor cells in blood. Fluorescent tumor cells in mouse blood were isolated and counted 38 days after tumor cell inoculation. EV empty
vector, KD knockdown, LM lung metastatic cell line derived from MDA-MB-231
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Tyr204P, ERK1/2, AKT-Tyr416P, AKT, and BCL2L11
from Cell Signaling Technologies (Boston, MA, USA);
anti-HIF1A from Novus Biologicals (Littleton, CO, USA);
anti-SMARCE1 and SMARCA4 from Bethyl Laboratories
(Montgomery, TX, USA); anti-GAPDH from Millipore
(Merck, Darmstadt, Germany) and anti-TBP from Abcam
(Cambridge, MA, USA).
Chromatin immunoprecipitation (ChIP)
Cells (2 × 107) were crosslinked with 1 % formaldehyde
(Pierce™ 16 % formaldehyde (w/v), methanol-free, Life
Technologies) for 15 minutes. The nuclear fraction was
prepared using the NE-PER™ Nuclear and Cytoplasmic
Extraction Reagents (Life Technologies), chromatin was
sheared by sonication to obtain approximately 500 bp
fragments and the soluble fraction was collected after
centrifuge (12,000 rpm, 15 min). The soluble nuclear
fractions were pre-cleaned with control IgG and Magna-
Bind Goat anti-Rabbit IgG (Life Technologies) and
used for immunoprecipitation with antibodies against
HIF1A, SMARCE1 or SMARCA4. Immunocomplexes
were isolated with MagnaBind Goat anti-Rabbit IgG, de-
crosslinked, and subjected to DNA preparation using the
MiniElute PCR Purification Kit (QIAGEN, Germantown,
MD, USA). qPCR was performed to detect the presence
of PTK2 promoter region by using primers (Forward:
5′-CTCTTCCTCCTCCTGCCTCT-3′; reverse 5′-GTT
CGGGGAAGACAGAAA GG-3′). To detect protein-
protein interaction, the immunocomplexes were dissolved
in Laemmli Sample Buffer (Bio-Rad) and subjected to im-
munoblotting assay.
Caspase assay
A total of 5 × 105 cells were plated in polyHEMA-coated
dishes and caspase-3 levels were measured at indicated
time points by using the Caspase-Glo® 3/7 assay kit
(Promega, Madison, WI, USA). Caspase activity was
calculated as per manufacturer protocol, normalized
to cell numbers.
Nucleosome scanning assay (NUSA)
106 cells were placed under suspension culture in poly-
HEMA-coated dishes for 0, 0.5, 1 and 2 hours. Nuclei
were isolated, treated with Atlantis double-strand specific
DNase (dsDNase) and subjected to DNA purification ac-
cording to the EZ Nucleosomal DNA Prep Kit (Zymo Re-
search, Irvine, CA, USA). qPCR was performed to
determine nucleosome positioning on the PTK2 pro-
moter. Overlapping primers were designed from −150 to
+1589 relative to start site of PTK2 promoter to generate
amplicons of approximately 150 bp, the size of DNA cov-
ered by one nucleosome. DNA amount was calculated ac-
cording to a standard curve (qPCR CTs vs. various
concentrations of template) generated for each primer
and normalized to qPCR CTs of DNA purified from equal
number of nuclei untreated with dsDNase.
Fig. 2 SMARCE1 knockdown reduces lung colonization of tumor cells inoculated through tail veins. a Number of circulating tumor cells in blood
collected at various times after tail vein injection in NSG mice. b Fluorescent tumor cells in lungs of NSG mice 72 h after tail vein injection. Representative
images of five lungs for each group were shown. c Fluorescent tumor foci in the left lung lobes of NSG mice 4 weeks after tail vein injection of tumor
cells. The area of tumor foci on the dorsal surface of the left lung lobe was quantified by ImageJ
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Statistical analysis
Analysis of variance (ANOVA) and post hoc least signifi-
cant difference analysis or t tests were performed using
GraphPad Prism 5 software (Graphpad, San Diego,
CA, USA). p values < 0.05 (*) were considered statistically
significant. Data from two or three independent experi-
ments with replicates are presented as means ± standard
deviation (SD).
Results
SMARCE1 knockdown reduces lung metastasis of breast
cancer in vivo
To define the role of SMARCE1 in breast cancer metas-
tasis, we examined the effect of SMARCE1 knockdown
(KD) on spontaneous lung metastasis using an orthotopic
xenograft mouse model derived from a lung metastatic
variant of MDA-MB-231 cells, which was previously
described and designated as LM [13]. SMARCE1 knock-
down showed no significant effect on the latency and
growth rate of primary xenografts in mammary gland fat
pads (Fig. 1a and b, LM-SMARCE1-KD vs. LM-EV),
but substantially reduced both the number and size of
metastatic foci in lungs (Fig. 1c, LM-SMARCE1-KD vs.
LM-EV). According to the images of lung tissue sections,
metastatic foci occupied 12.30 ± 3.87 % of the lung paren-
chyma in mice 6 weeks after inoculation with LM-EV
cells, which was reduced to 1.02 ± 0.76 % in mice inocu-
lated with LM-SMARCE1-KD cells (p = 0.0002) (Fig. 1c
bar graph). By examining the number of tumor cells in
blood, we found that SMARCE1 knockdown significantly
reduced the number of circulating tumor cells (p = 0.0011)
(Fig. 1d). Together, these results suggest that SMARCE1
activity is dispensable for primary tumor outgrowth, but
essential for distant metastasis of MDA-MB-231 cells.
Fig. 3 SMARCE1 knockdown promotes cell migration, but sensitize cells to anoikis. a Effect of SMARCE1 knockdown in LM cells on cell migration
and invasion. Boyden chambers, uncoated or coated with Matrigel were used to measure cell migratory and invasive potential, respectively. b Effect of
SMARCE1 knockdown in LM cells on viability of cells cultured in dishes coated with polyHEMA to prevent adhesion. c Effect of SMARCE1 knockdown
in HCC38 cells. d SMARCE1 overexpression in BT549 cells. e Blocking SMARCE1 expression by siRNA enhanced detachment-induced caspase activation
in LM and HCC38 cells. Accell SMARTpool of SMARCE1-siRNA (1 μM) were delivered into cells 48 h prior to detachment. Caspase activities
were determined at indicated time points after cell detachment by using the Caspase-Glo 3/7 assay kit. *p < 0.05, Student t test. EV empty
vector, KD knockdown, LM lung metastatic cell line derived from MDA-MB-231
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SMARCE1 knockdown reduces lung colonization of tumor
cells inoculated through tail vein
Metastasis is a multistep process involving local inva-
sion, circulation, extravasation, colonization, and out-
growth of metastatic foci [16]. To identify the steps of
the metastatic cascade that requires SMARCE1 activity,
we examined the effect of SMARCE1 knockdown on the
ability of tumor cells to survive circulation and colonize
lungs by using an experimental metastasis model. LM-
EV and LM-SMARCE1-KD cells (5 × 105) were injected
into the left lateral tail vein of 5-week-old female NSG
mice. Tumor cells in the bloodstream and lung tissues
were examined at various times after injection (Fig. 2a).
As expected, the number of circulating tumor cells in
blood decreased over time. Interestingly, at any given
time point, the number of LM-EV cells in the blood-
stream was significantly higher than that of the LM-
SMARCE1-KD cells (Fig. 2a). At 72 hours past tail vein
injection, we observed tumor cells in the lungs of mice
inoculated with LM-EV cells but not in mice with LM-
SMARCE1-KD cells (Fig. 2b). Four weeks post injection,
a lower number of tumor foci was observed in lungs of
mice inoculated with LM-SMARCE1-KD cells than that
in mice with LM-EV cells (Fig. 2c). Together, these re-
sults suggest that SMARCE1 knockdown diminish the
ability of tumor cells to survive circulation.
SMARCE1 knockdown sensitizes tumor cells to anoikis
Our in vivo experiment results implicate that SMARCE1
plays an essential role in distant metastasis of breast
cancer cells by promoting the survival of circulating
tumor cells. However, it is unclear whether SMARCE1
plays a role in early metastatic events such as cell migra-
tion and invasion. To examine the effect of SMARCE1
Fig. 4 SMARCE1-mediated anoikis resistance requires activation of PTK2, ERK, and AKT pathways. a Viability of LM-EV and LM-SMARCE1-KD cells
cultured in polyHEMA-coated dishes in the absence or presence of indicated inhibitors. b Viability of BT549-EV and BT549-SMARCE1 cells cultured
in polyHEMA-coated dishes in the absence or presence of indicated inhibitors. For all experiments, viable cells were counted after 7 days in
suspension culture. Concentration of inhibitors: 0.5 μM PF562271, 10 μM U0126, 10 μM PD98059, 30 μM ZSTK474, 3 μM dasanitib, 5 μM DAPT,
and 10 μM LY2109761. *p < 0.05, Student t test. EV empty vector, KD knockdown, LM lung metastatic cell line derived from MDA-MB-231
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knockdown on the migratory and invasive potential of
tumor cells, we performed Boyden chamber transwell
assays. Cells were plated in the uncoated Boyden cham-
ber to measure their migratory potential, then in a
Matrigel-coated chamber to determine their invasive-
ness. As showed in Fig. 3a, SMARCE1 knockdown in
LM cells significantly increased cell migratory potential,
but showed no significant effect on cell invasiveness.
This observation suggests that SMARCE1 activity is
dispensable for cell migration and invasion. Next, we
examined the effect of SMARCE1 knockdown on cell
sensitivity to anoikis by monitoring cell viability after
culture in dishes coated with polyHEMA to prevent at-
tachment. As showed in Fig. 3b, SMARCE1 knockdown
in LM cells substantially reduced the number of viable
cells cultured in suspension. This result is consistent
with our results from in vivo experiments and confirms
that SMARCE1 plays a key role in protecting LM cells
against anoikis.
To determine whether SMARCE1-mediated anoikis
resistance can be extended to other breast cancer cell
lines, we examine the effect of SMARCE1 knockdown in
HCC38 (Fig. 3c), a triple-negative breast cancer cell
line. We found that SMARCE1 knockdown resulted
in significant reduction of the viability of cells in suspension
culture. In addition, we examined the effect of SMARCE1
overexpression in BT549, a triple-negative breast cancer
cell line that lacks SMARCE1 expression due to a biallelic
inactivating mutation that causes a frameshift [17]. As
expected, no SMARCE1 mRNA or protein was detected in
BT549 cells (Fig. 3d). Enforced SMARCE1 expression
in BT549 substantially increased the viability of cells in
suspension culture. To validate the observations with
SMARCE1-shRNA, we examined the effect of SMARCE1
siRNA (Accell SMARTpool, GE Dharmacon) or control
oligonucleotides on anoikis in LM and HCC38 cell lines.
As showed in Fig. 3e, SMARCE1 siRNA (SMARCE1-i)
treatment resulted in decreased expression of SMARCE1
protein and enhanced activation of caspase 3/7 in cells
under suspension culture. These results demonstrate
that SMARCE1 plays role in anoikis resistance of breast
cancer cells.
SMARCE1-mediated anoikis resistance requires activation
of PTK2, ERK and AKT pathways
To gain insights into the molecular mechanisms under-
lying SMARCE1-mediated anoikis resistance, we sought
to identify signaling pathways regulated by SMARCE1 in
detached cells by using chemical inhibitors of several
signaling pathways that have been linked to anoikis re-
sistance of cancer cells [18, 19]. As showed in Fig. 4a, in-
hibitors of focal adhesion kinase (PTK2/FAK), ERK, and
AKT significantly reduced the viability of LM-EV cells in
suspension culture. In contrast, these inhibitors showed
no significant effect on LM-SMARCE1-KD cells. The same
experiments were performed with BT549-EV and BT549-
SMARCE1 cells and the result showed that SMARCE1-
mediated increase of cell viability was effectively abolished
by inhibitors of PTK2, ERK, and AKT (Fig. 4b). In agree-
ment with the observed effects of chemical inhibitors on
Fig. 5 SMARCE1-dependent activation of PTK2, ERK, and AKT pathways by cell detachment. a Effect of SMARCE1 knockdown in LM cells on
detachment-induced activation of pro-survival (FAK/PTK2, ERK, and AKT) and pro-apoptotic (BIM) signaling pathways. b Effect of SMARCE1
knockdown in HCC38 cells. c Effect of SMARCE1 overexpression in BT549 cells. The levels of protein expression and phosphorylation were
determined by immunoblotting assays. GAPDH was included as a loading control. EV empty vector, KD knockdown, LM lung metastatic
cell line derived from MDA-MB-231
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cell viability, immunoblotting analysis showed that LM-EV
cells in suspension culture had higher levels of PTK2 pro-
tein, ERK phosphorylation, and AKT phosphorylation
than LM-SMARCE1-KD cells (Fig. 5a). In addition, el-
evated expression of the pro-apoptotic protein BCL2-
interacting mediator of cell death (BIM)/BCL2L11, a
marker of onset of anoikis in breast cancer cells, was
detected in suspension cultures of LM-SMARCE1-KD
cells, but not in LM-EV cells (Fig. 5a). Similarly, higher
levels of PTK2 protein and AKT phosphorylation, con-
comitant with lower levels of BIM protein, were observed
in HCC38-EV cells as compared to HCC38-SMARCE1-
KD cells in suspension culture (Fig. 5b). However, ERK
phosphorylation was not affected by cell detachment
or SMARCE1 knockdown in the HCC38-EV cells. In
addition, elevated expression levels of PTK2 protein,
ERK phosphorylation, and AKT phosphorylation, but
diminished levels of BIM, were detected in BT549-
SMARCE1 cells in comparison to control BT549-EV cells
under suspension culture (Fig. 5c). Together, these results
suggest that activation of PTK2, ERK, and AKT pathways
is critical for breast cancer cells to survive anoikis, and
SMARCE1 activity is required for the activation of these
survival pathways in detached cells.
SMARCE1 collaborates with HIF1A to activate PTK2
transcription in detached cells
Aberrant activation of PTK2, a non-receptor tyrosine
kinase that is involved in focal adhesion, has been recog-
nized as a key mediator of anoikis resistance in variety
of tumor cells [18, 20]. For example, PTK2 activation was
detected in circulating tumor cells isolated from 90 % of
patients with metastatic breast tumors, implicating a role
of PTK2 in breast cancer metastasis [21]. Therefore, we
sought to examine whether SMARCE1 regulates PTK2
expression in detached cells. Based on immunoblotting
and quantitative polymerase chain reaction (qPCR)
analysis, we found that cell detachment induced PTK2
Fig. 6 SMARCE1 collaborates with HIF1A to activate PTK2 transcription in detached cells. a Detachment-induced PTK2 mRNA expression is abolished
by SMARCE1 knockdown in LM and HCC38 cells, whereas enhanced by SMARCE1 overexpression in BT549 cells. b Detachment-induced recruitment of
HIF1A and SMARCA4 to the promoter region of PTK2 is diminished by SMARCE1 knockdown in LM cells. Chromatin binding of HIF1A, SMARCE1, and
SMARCA4 was measured by ChIP-qPCR assay. Average fold enrichment of PTK2 promoter DNA by indicated antibodies (vs. control IgG) from three
independent experiments were presented. c Detachment induces interaction between SMARCE1 and HIF1A in LM-EV and LM-SMARCE1-KD cells. The
protein interaction was examined by immunoprecipitation/immunoblotting assays. *p < 0.05, Student t test. EV empty vector, KD knockdown, LM lung
metastatic cell line derived from MDA-MB-231
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expression at both protein level (Fig. 5) and mRNA level
(Fig. 6a) in a SMARCE1-dependent manner in LM,
HCC38, and BT549 cells. This observation suggests that
SMARCE1 is required for transcription activation of PTK2
gene in detached cells.
By inspecting the transcription factor binding se-
quences in the proximal promoter region of PTK2 gene
(Fig. 6b), we found a potential HIF1A/ARTN binding
site located in the binding region of SWI/SNF subunits
(i.e., SMARCA4 and SMARCB1) identified by ENCODE
TFBS ChIP-seq analysis [22]. Normoxic HIF1A activa-
tion has been linked to anoikis resistance in breast can-
cer cells [21, 23]. In addition, SWI/SNF complexes were
reported to play a role in modulating HIF1A-mediated
transcription activation in cells under hypoxia [24, 25].
Therefore, we speculated that SMARCE1 regulates
PTK2 gene transcription through HIF1A in detached
cells. By using ChIP-qPCR assay, we showed that cell de-
tachment induced recruitment of SMARCE1, HIF1A,
and BRG1/SMARCA4 to the PTK2 promoter region
(−874 to −575 bp) in LM-EV cells, which was abolished
by SMARCE1 knockdown (Fig. 6b). In addition, recipro-
cal immunoprecipitation assays, we detected HIF1A and
SMARCE1 proteins in the immunoprecipitated SMARCE1
and HIF1A complexes, respectively (Fig. 6c). These results
suggest that SMARCE1 activity is required for HIF1A-
mediated PTK2 transcription activation in detached cells.
To examine the consequence of SMARCE1 and HIF1A
binding to the PTK2 promoter in detached cells, nucleo-
some scanning assay (NUSA) was performed to examine
nucleosomal positioning on the PTK2 promoter. We
found that cell detachment induced nucleosomal disas-
sembly on the PTK2 promoter region bound by HIF1A
and SMARCE1, indicated by decreased amount of DNA
detected by qPCR as a result of increased sensitivity of
PTK2 promoter to dsDNase digestion (Fig. 7). However,
cell detachment did not increase dsDNase sensitivity in
LM-SMARCE1-KD cells (Fig. 7b, right panel). These obser-
vations provide evidence supporting a role of SMARCE1 in
HIF1A-mediated PTK2 transcriptional activation by chro-
matin remodeling in detached cells.
HIF1A activates PTK2 transcription and downstream
activation of survival pathways in detached cells
To confirm that HIF1A-mediated PTK2 transcription is
critical for breast cancer cell to survive anoikis, we
Fig. 7 SMARCE1 orchestrates chromatin remodeling of PTK2 promoter in detached cells. a Overlapping primer designed for the nucleosome
scanning assay and their amplicon sizes. The location of each primer set is given relative to the transcription start site (TSS). b Significant nucleosomal
displacement is observed on PTK2 promoter (from −802 to −492 bp) in LM-EV cells after 0.5, 1, and 2 hours under suspension culture (vs. adherent
cells), but not in LM-SMARCE1-KD cells. Results from three independent experiments were presented as means ± SE. EV empty vector, KD knockdown,
LM lung metastatic cell line derived from MDA-MB-231
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examined the effect of HIF1A knockdown on cell sensi-
tivity to anoikis and detachment-induced activation of
PTK2, ERK, and AKT. HIF1A knockdown in MDA-MB-
231 cells effectively dampened detachment-induced
HIF1A protein accumulation and PTK2 mRNA expres-
sion (Fig. 8a and b), and reduced the number of viable
cells in suspension culture (Fig. 8c). Immunoblot ana-
lysis showed that the levels of PTK2, phosphorylated-
PTK2 (pTyr576/577), phosphorylated-ERK (pThr202/
Tyr204), and phosphorylated-AKT (pTyr416) were signifi-
cantly lower in HIF1A-KD cells than that in control MDA-
MB-231-EV cells under suspension culture (Fig. 8d).
Conversely, the pro-anoikis protein BIM was induced
only in detached HIF1A-KD cells. To confirm that ERK
and AKT phosphorylation are downstream events of
PTK2 activation in detached cells, we examined the
effect of PTK2 inhibition by PF562271 on activation of
these pathways. As showed in Fig. 8e, pre-treatment with
PF562271 effectively abolished detachment-induced
phosphorylation of PTK2, ERK, and AKT. Taken
together, these results suggest that HIF1A-mediated
PTK2 transcription activation plays a key role in pro-
tecting cells against anoikis by sustaining the activation of
survival signaling pathways (i.e., ERK and AKT), as well as
suppressing pro-apoptotic signaling (i.e., BIM).
To corroborate the role of PTK2 in SMARCE1-
mediated anoikis resistance, we examined the effects of
PTK2 overexpression and PTK2 knockdown on anoikis
sensitivities of LM-SMARCE1-KD and BT549-SMARCE1
cells, respectively. We found that PTK2 overexpression ef-
fectively rescued LM-SMARCE1-KD cells from anoikis,
indicated by increased number of viable cells and reduced
caspase activation (Fig. 9a–d). Conversely, PTK2 knock-
down abolished SMARCE1-mediated protection of BT549
cells against anoikis (Fig. 9e–f ).
SMARCE1 knockdown sensitizes non-tumorigenic
mammary epithelial cells to anoikis
To examine whether the SMARCE1-dependent anoikis re-
sistance occur at early stage of tumorigenesis, we examined
Fig. 8 HIF1A activates PTK2 transcription and downstream survival pathways in detached cells. a Detachment induced HIF1A protein
accumulation is eliminated by HIF1A knockdown in MDA-MB-231 cells. b HIF1A knockdown abolishes detachment induced PTK2 mRNA
expression in MDA-MB-231 cells. c HIF1A knockdown sensitizes MDA-MB-231 cells to anoikis. Viable cells in suspension culture for 10 days
were counted. d Effect of HIF1A knockdown in MDA-MB-231 cells on detachment-induced activation of pro-survival (PTK2, ERK, and AKT)
and pro-apoptotic (BIM) signaling pathways. e Effect of PTK2 inhibition in MDA-MB-231 cells on detachment-induced activation of pro-survival and
pro-apoptotic signaling pathways. The mRNA levels were measured by qPCR. The levels of protein expression and phosphorylation were determined
by immunoblotting assays with GAPDH included as a loading control. *p < 0.05, Student t test. EV empty vector, KD knockdown, LM lung metastatic
cell line derived from MDA-MB-231
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the effect of SMARCE1 knockdown on anoikis sensitivity
of 184B5, a mammary epithelial cell line immortalized by
benzo(a)pyrene exposure [26]. Previous studies showed that
184B5 was not tumorigenic in immunosuppressed mice,
but did form colonies in semisolid medium [26]. Therefore,
184B5 represents cells at early stage of tumorigenesis. We
found that SMARCE1 inhibition in 184B5 cells, by either
stable knockdown through shRNA expression (Fig. 10a) or
transient siRNA delivery (Fig. 10b), blocked detachment-
induced PTK2 upregulation (Fig. 10c) and sensitized cells
to anoikis, indicated by reduced cell viability and increased
caspase activation (Fig. 10a and b, respectively). These ob-
servations suggest that SMARCE1/PTK2-mediated anoikis
resistance is an early event of tumorigenesis.
Higher SMARCE1 and PTK2 expression is associated with
poor prognosis of patients with basal-like or luminal B
subtype of breast tumors
Having established a role of SMARCE1 in regulating
metastatic potential of breast cancer cells through the
HIF1A/PTK2 pathway, we sought to examine the clinical
relevance of this finding by examining the relationship
between the SMARCE1 and PTK2 expression and the
clinical outcomes of breast cancer patients. By analyzing
the expression data of 3554 breast tumor samples collected
by an online Kaplan-Meier survival analysis tool [27], we
found that higher expression of SMARCE1 or PTK2 is as-
sociated with shorter interval of relapse-free survival (RFS)
of breast cancer patients (Fig. 11a). Next, we examined the
Fig. 9 PTK2 activation is essential for SMARCE1-mediated anoikis resistance in breast cancer cells. a Expression levels of PTK2 mRNA in LM
derivatives. b PTK2 protein expression and phosphorylation in LM derivatives cultured in polyHEMA-coated dishes. c Effect on PTK2 overexpression on
viability of LM derivatives cultured in polyHEMA-coated dishes. d Effect on PTK2 overexpression on caspase activation in LM derivatives cultured in
polyHEMA-coated dishes. Caspase activity was normalized to cell numbers and results from three independent experiments were presented as
means ± SE. e Expression levels of PTK2 mRNA in BT549 derivative. f Effect of PTK2 knockdown on viability of BT549 derivative cultured in
polyHEMA-coated dishes. *p < 0.05, Student t test. EV empty vector, KD knockdown, LM lung metastatic cell line
derived from MDA-MB-231
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relationship between the expression of SMARCE1 and
PTK2 in breast tumors in The Cancer Genome Atlas
(TCGA) database [28]. No significant correlation be-
tween SMARCE1 and PTK2 expression was detected
when data from all breast tumors (n = 825) were in-
cluded in the analysis. However, after tumors were
stratified according to the intrinsic PAM50 subtype
markers, a positive correlation between SMARCE1 and
PTK2 expression was detected in the luminal B and basal-
like cohorts (Fig. 11b), but not in the ERBB2-enriched or
luminal A cohorts. Together, these observations suggest
that higher expression of SMARCE1 and PTK2 increases
risk of tumor relapse, and SMARCE1 likely plays a key role
in regulating PTK2 expression in luminal B and basal-like
tumors.
Genomic alterations contribute to deregulation of
SWI/SNF complexes in breast cancer
Despite the prevalent notion that SWI/SNF complexes
are tumor suppressors [29], emerging evidence suggests
that genetic alterations of subunit genes can produce
aberrant SWI/SNF complexes with oncogenic function
[30]. These findings promoted us to examine the nature
and frequency of genetic alterations in SMARCE1 and
other SWI/SNF subunits specifically in breast cancer by
using the TCGA database. The result revealed that ap-
proximately 30 % of breast tumors harbor genetic alter-
ations in one or more of the genes encoding SWI/SNF
subunits (Fig. 11c). Intriguingly, gene amplification is the
most frequent genetic event for multiple SWI/SNF sub-
units in breast cancer, rather than inactive mutations
that were reported in other tumors [6]. SMARCE1 is the
second most frequently amplified gene among all the
SWI/SNF subunits. This finding implicates an oncogenic
role of SWI/SNF complexes in human breast cancer. If a
SWI/SNF subunit plays a critical role in promoting pro-
gression of breast cancer, we speculate a positive correl-
ation between its expression and poor prognosis of breast
cancer patients. Therefore, we examined the relationship
between the expression of each SWI/SNF subunit and
interval of RFS of breast cancer patients by using the on-
line Kaplan-Meier survival analysis tool [27]. This analysis
Fig. 10 Blocking SMARCE1 expression sensitizes non-tumorigenic mammary epithelial cells to anoikis. a Effect of SMARCE1 knockdown by
stable shRNA expression on viability of 184B5 cells cultured in polyHEMA-coated dishes. b Effect of stable shRNA expression (SMARCE1-KD) and
SMARCE1-siRNA delivery (SMARCE1-i) on caspase activation in 184B5 cells cultured in polyHEMA-coated dishes. Caspase activity was measured by
using the Caspase-Glo 3/7 assay kit and normalized to cell numbers. The results from three independent experiments were presented as
means ± SE. c Detachment-induced PTK2 mRNA expression is abolished by SMARCE1-KD or SMARCE1-i in 184B5 cells. mRNA levels were
measured by qPCR. EV empty vector, KD knockdown
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revealed that higher expression of nine (out of 31)
SWI/SNF subunits (i.e., BCL7C, BRD7, ACTL6A,
SMARCE1, SMARCA5, SMARCAL1, SMARCA4, SS18,
and SMARCC1) is associated with shorter interval of RFS
of breast patients (log-rank p < 0.05, n = 3550). Overall
these results from genetic and expression data analysis
suggest that deregulation of SWI/SNF activity likely play a
key role in promoting breast cancer progression.
Discussion
Loss of adhesion to proper extracellular matrix (ECM)
triggers a specific form of apoptosis termed anoikis in
normal epithelial cells [31], which plays a fundamental
role in morphogenesis of the mammary gland ductal sys-
tem [32]. Circumvention of anoikis contributes to breast
tumor development and is a prerequisite for metastases
by allowing cells to survive loss or alterations of ECM
[3, 18]. In mammary epithelial cells, the dynamic and
magnitude of activation of pro-apoptotic genes (e.g.,
BIM and BMF) or pro-survival proteins (e.g., PTK2)
were shown to play a critical role in determining the
fates of detached cells, anoikis or survival [3, 18, 33, 34].
PTK2 is one of the most important signaling proteins re-
cruited into focal adhesions upon cell-ECM contact,
where PTK2 is rapidly autophosphorylated to enable the
recruitment of other scaffold and signaling molecules to
activate the downstream cell survival signaling pathways
(e.g., PI3K/Akt and MAPK/ERK pathways) [20, 34, 35].
Emerging evidence suggests that PTK2 plays a key role
in protecting tumor cells against anoikis by sustaining
survival signaling [18, 20]. However, how PTK2 is acti-
vated in detached cells have not been definitively resolved.
Our studies revealed a key role of SMARCE1 in promot-
ing survival of detached cells by facilitating rapid PTK2
transcription activation through HIF1A, the master regu-
lator of hypoxia-responsive genes. Multiple kinases were
Fig. 11 Higher SMARCE1 and PTK2 expression is associated with poor prognosis of breast cancer patients. a Kaplan-Meier analysis of
recurrence-free survival (RFS) of breast cancer patients based on SMARCE1 and PTK2 expression using a dataset of 3554 breast tumor samples
(http://kmplot.com/analysis/). To construct Kaplan-Meier curves all percentiles between the lower and upper quartiles were computed and the best
performing threshold was used as cutoff to divide the patient cohort. The log-rank test p value was calculated by using RFS up to 15 years as end
point. b Correlated expression of SMARCE1 and PTK2 in basal-like and luminal B subtypes of breast cancer according to the TCGA database. Tumors
with PTK2 amplification were excluded from the correlation analysis. c Frequency of genetic alterations of SWI/SNF complex subunits in breast tumors
according to the TCGA database
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reported to activate PTK2 through phosphorylation at
Tyr576/577 in detached cells, including SRC family ki-
nases and PTK6 [18, 36]. We found that SRC inhibition
by dasatinib had no effect on viability of LM and BT549
cells under suspension. This observation suggests that
PTK2 phosphorylation in detached breast cancer cells is
likely sustained by a SRC-independent mechanism.
HIF1A activation under normal oxygen tension has
been linked to anoikis resistance of breast cancer cells
driven by ERBB2 oncogene [23], and circulating breast
tumor cells from patients with metastatic breast cancer
[21]. SWI/SNF complexes were shown to regulate tran-
scription activation of a subset of HIF1A target genes
under hypoxia [25]. However, it is unclear whether
SWI/SNF complex is required for HIF1A transcription
activity in detached cells under normal oxygen tension.
Our study provides evidence suggesting an essential
role of SMARCE1-based chromatin remodeling activity in
breast cancer metastasis by facilitating HIF1A-mediated
PTK2 transcription activation in detached cells under
normoxia. Future study is warranted to evaluate the anti-
metastasis potential of approaches targeting SMARCE1-
HIF1A interaction.
According to the database of Project Achilles that
performed genome-wide pooled shRNA screens across
hundreds of cancer cell lines to identify genes essential for
tumor cell proliferation, SMARCE1 knockdown showed
limited effect on proliferation of breast cancer cells [37].
Consistently, we found that SMARCE1 knockdown had
no significant effect on proliferation of two breast cancer
cell lines (i.e., MDA-MB-231 and HCC38) in vitro and
growth of orthotopic xenografts derived from MDA-
MB-231 cells, while significantly enhanced anoikis sensi-
tivity of breast cancer cells. These findings suggest that
SMARCE1 is dispensable for proliferation of breast cancer
cells under normal growth condition, but required for
cells to survive anoikis. Whether SMARCE1 plays a role
to protect cells against stress-induced cell death in general
warrants further investigation.
In contrast to colorectal, melanoma and lung cancer
where inactive mutations of SWI/SNF subunits frequently
occur, breast tumors have low frequency of inactive muta-
tions [6, 10, 11]. By inspecting the TCGA database we
found that approximately 30 % breast tumors harbor gen-
etic alterations (i.e., gene amplification, deletion, and muta-
tion) in one or more of the SWI/SNF subunits, with gene
amplification being the most frequent event. This finding
implicates an oncogenic role of SWI/SNF complexes in
breast cancer. Consistently, we found that higher expression
of several SWI/SNF subunits is associated with shorter
interval of RFS of breast cancer patients. Our findings are
likely relevant to basal-like and luminal B breast tumors, be-
cause a positively correlated expression between SMARCE1
and PTK2 is evident in these subtypes of tumors.
Conclusion
This study establishes a novel role of SMARCE1 in regu-
lating metastatic potential of breast cancer cells by pro-
moting survival of detached cells through the HIF1A/
PTK2 pathway.
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